

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KIM *et al.*

Appl. No.: 10/646,145

Filed: August 22, 2003

For: **Composition Comprising the
Extract of *Actinidia arguta* and
Related Species for the Prevention
and Treatment of Allergic Disease
and Non-allergic Inflammatory
Disease**

Confirmation No.: 8727

Art Unit: 1627

Examiner: SOROUS, Layla

Atty. Docket: 2298.0140001/TJS/M-N

Sixth Supplemental Information Disclosure Statement

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98. The numbering on this Sixth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Fifth Supplemental Information Disclosure Statement filed on June 7, 2010, in connection with the above-captioned application.

Copies of documents **FP15-FP16** and **NPL18-NPL22** are submitted.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language documents **FP15-FP16**, cited on the IDS Form PTO/SB/08A:

Document **FP15**, CN 1107308 A, is in the Chinese language. An English language abstract of document FP15 is cited as document **NPL18**.

Document **FP16**, KR 2001-0096881, is in the Korean language. An English language abstract of document FP16 is cited as document **NPL19**.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Timothy J. Shea, Jr.
Attorney for Applicants
Registration No. 41,306

Date: August 23, 2010

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

1245889_1.DOC